The purpose of the study is to evaluate the safety, tolerability and effect on leukocyte and plasma Iduronate 2-Sulfatase (IDS) enzyme activity of ascending doses of SB-913. The company is now putting its hopes on increasing the dosage of SB-913. Three doses of SB-913 are being tested: 5x1012vg/kg, 1x1013vg/kg, and 5x1013vg/kg. Ex vivo gene-edited cell therapy is the most straightforward application of ZFN technology. For fiscal 2018 and fiscal 2019, Sangamo is expected to generate revenues of $82.73 million and $89.39 million, respectively. The glimmer of hope here for Sangamo is patient six, whose transient plasma IDS expression might hint at a dose response and the potential for higher dosing. No measurable reduction in urine GAGs was identified in any patients, contrary to an earlier update from the same trial (Zinc fingers get the thumbs down, September 6, 2018). The case for Sangamo Therapeutics Year after year, Sangamo publishes a study that proves its zinc-finger nuclease (ZFN) technology is superior to all other gene editing methods in … But patient six was the only one to show a jump in plasma IDS, though this faded after liver enzyme elevations were seen. Sangamo's ZFP-TF technology involves introducing an engineered zinc finger protein (ZFP) which is designed to identify and bind to a precise sequence of DNA. Novartis is the latest big drug firm to strike a collaboration with Sangamo Therapeutics. The theory was that this would result in an increase in IDS production and a reduction in GAGs, with the ultimate hope that patients could be safely taken off ERT. Instead, Gilead will partner with Sangamo Therapeutics, a Richmond, Calif.-based company that pioneered an older gene-editing tool called the zinc finger nuclease (ZFN). In the low-dose group, one patient had no evidence of gene integration and one was not evaluable, being unable to undergo liver biopsy. The ZFNs make a double stranded break in the DNA in a precise location in the albumin gene, where the transgene is permanently integrated using the cell’s natural repair mechanism. Replace a gene, replace a weekly infusion. Unfortunately, it might be the case that its older technology is not potent enough to have a therapeutic effect in this or any other disorder. Yesterday's presentation cast doubt on most of those hypotheses. ZFN has a much longer track record than CRISPR does. Global Zinc Finger Nuclease Technology Market 2020-2025 (Impact of Covid-19) | Sigma-Aldrich, Sangamo Therapeutics, Labomics, Thermo Fisher Scientific, Gilead, etc. Sangamo Therapeutics, Inc. is a Brisbane, California-headquartered clinical-stage genomics medicines company that is a pioneer in the research and development of zinc finger … But, even if more persuasive biomarker signs emerge, the study might not be sufficient for a regulatory filing. Sangamo's chief executive Sandy Macrae yesterday talked up second-generation gene-editing projects that the company hopes will be more potent and that should enter the clinic later this year. The current standard of care is enzyme replacement therapy (ERT) with Shire's Elaprase, but this requires weekly infusions. By cutting DNA at a precise spot in the genome, DNA can be removed, added or replaced for therapeutic effect. Are the stars waning for Pfizer’s haemophilia A gene therapy? Highlighted Sangamo’s zinc finger protein in vivo genome regulation programs and capabilities and research detailing Sangamo’s engineered adeno-associated virus (AAV) ... Net loss attributable to Sangamo Therapeutics, Inc. stockholders $ (35,929 ) $ (30,284 ) $ (78,842 ) $ On the question of whether the IDS gene had been integrated, Sangamo reported mixed results. Aducanumab tops 2021’s biggest potential launches, The pandemic releases its grip on clinical trials, 2020 drug approvals rise despite Covid-19, Merck KGaA’s dual immuno-oncology weapon misfires, Zinc finger protein nuclease associated IDS gene editing, Zinc finger protein nuclease associated factor IX gene editing, Zinc finger protein nuclease associated IDUA gene editing, Zinc finger protein nuclease edited cell therapy. We engineer ZFNs for precision, efficiency, and specificity, which we believe are the critical parameters for a therapeutic genome editing technology. Sangamo Therapeutics is at the forefront of a new era of genomic medicine that aims to transform the lives of people living with serious diseases. Snippet roundup: Wins for AcelRx, Foamix and SGLT2 developers. ZFP Technology Platform. It is little solace to Sangamo investors that the group's lead genome editing project, SB-913, seems to do what it is supposed to – edit a genetic mutation that leads to an enzyme deficiency. Replace a gene, replace a weekly infusion. Genome editing works by using enzymes called “engineered nucleases” that act like molecular scissors. Our zinc finger nuclease (ZFN) technology is based on a naturally occurring class of proteins called zinc finger DNA-binding proteins (ZFPs), which recognize and bind to specific sequences of DNA. SB-913 is an intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for genome editing. BRISBANE, Calif., March 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, announced today the publication in Nature Communications of improvements to its zinc finger nuclease (ZFN) platform technology, which yield a 64-fold increase in the diversity of ZFNs available for targeting any DNA segment. But one mid-dose patient resumed ERT after three months when he experienced fatigue and an increase in urinary GAGs. zealinsider January 7, 2021 0 Our zinc finger nuclease (ZFN) technology is based on a naturally occurring class of proteins called zinc finger DNA-binding proteins (ZFPs), which recognize and bind to specific sequences of DNA. Our broad collection of publications, authored by our own scientists, collaborators, and others, contains original research articles and review articles that are relevant to our ZFP technology and its many applications. The contagion was not contained to just Sangamo and its older zinc finger nuclease genome editing technology; names like Crispr Therapeutics, Intellia, Editas Medicine and even Sarepta were also dragged down by this setback. Of the high dose group, one patient could not undergo biopsy to assess gene integration, and results from the other, patient six in the trial, are still pending. Sangamo’s zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation approach is designed to either selectively repress (down-regulate) or activate (up-regulate) the expression of a specific gene or DNA sequence with a single administration. Sangamo Therapeutics (formerly Sangamo BioSciences) hopes zinc fingers have the Midas touch when it comes to regulating gene expression. sangamo therapeutics inc (sgmo) - develops zinc finger dna-binding proteins for the therapeutic regulation of disease-associated genes. This would signal an even longer road to approval. Data from the first patients treated with hemophilia A therapy is expected this year. Sangamo's been advancing zinc finger gene editing tech for decades without a single late-stage clinical trial success to show for it. We use cookies on this website. Sangamo Therapeutics uses a different approach to gene editing called zinc-finger nuclease (ZFN) technology. About Sangamo’s Gene Regulation Platform Sangamo's zinc finger protein transcription factor (ZFP-TF) gene regulation technology is designed to either selectively repress (down-regulate) or activate (up-regulate) the expression of a specific gene or gene allele following a single administration. Sangamo Therapeutics is working with Pfizer on a hemophilia A gene therapy that doesn't use zinc-finger proteins. As this enzyme usually breaks down glycosaminoglycans (GAGs), these accumulate in MPS II patients, causing tissue and organ damage. Sangamo Therapeutics: The Promise of Zinc Fingers Real Estate Higher dose points Sangamo no closer to zinc finger success. Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. Tiny signs of a therapeutic benefit are offset by safety worries, as the company pivots to higher doses and second-generation projects. Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I | Sangamo Therapeutics, Inc. Novartis has agreed to license Sangamo Therapeutics’ zinc finger protein transcription factors (ZFP-TFs) to develop gene regulation therapies … Gilead’s Kite has struck a $3 billion deal to access Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology. The evidence so far suggests that changing the expression of the gene in question has not altered the course of the rare inherited disease in which the project was being tested, mucopolysaccharidosis type II (MPS II). Sangamo Therapeutics ; ASH 2020. By using this site, you agree that we may store and access cookies on your device. This technique has broad applicability, namely for the treatment of hemophilia B and other disorders. Kite will use the ZFN gene editing … Sangamo is not giving up yet. The Sangamo (NASDAQ: SGMO) tech uses proteins known as zinc finger nucleases that bind DNA to edit genes. JP Morgan day one roundup – disappointments set the tone. Sangamo Therapeutics recently presented what it characterized as key improvements to its technology platform for engineering highly specific zinc finger nucleases (ZFNs), which are used for targeted editing of the human genome. Once bound to the target sequence of DNA, a transcriptional repressor domain attached to the ZFP … Unlocking the potential for precise genetic cures Since our founding in 1995, Sangamo has been a leader in genomic medicine research and development. Sangamo and Pfizer are also collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene. Sangamo is best known for developing our proprietary gene editing technology, zinc finger nucleases (ZFNs). It applies cell and gene therapy to combat haemophilia and other genetic diseases. Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of … Sangamo is developing new genomic medicines which may address the underlying mistakes in DNA that lead to some genetic diseases. The latest round of data, released on Thursday at the World Symposium on lysosomal diseases, drove Sangamo shares down 31%, to levels not seen in two years. By way of comparison, Elaprase won approval with a 96-patient, 52-week trial that used pulmonary function and six-minute walk test as its endpoints. Genome editing makes permanent changes to the genetic code of a cell by correcting, disabling or modifying the DNA. It will be crucial that, when the biopsy results come back, they show the gene to have been successfully integrated. Sangamo’s genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), is currently delivered with AAVs and functions at the DNA level to selectively repress or activate the expression of specific genes to achieve a desired therapeutic effect. Further data on patients who have withdrawn from ERT, due later this year, will also be worth watching, the company claims. SCIENTIFIC AND MEDICAL PRESENTATIONS. The presentation concerned six subjects, two from each of the three dosing groups. The contagion was not contained to just Sangamo and its older zinc finger nuclease genome editing technology; names like Crispr Therapeutics, Intellia, Editas Medicine and even Sarepta were also dragged down by this setback. Our technology team continues to optimize ZFNs for the three key dimensions of genome editing: precision, efficiency, and specificity. Three patients were taken off ERT, two in the medium-dose group and one in the high-dose. Sangamo scientists today are presenting data demonstrating that the company’s engineered zinc finger protein transcription factors (ZFP-TFs) specifically and powerfully repress key genes involved in brain diseases including Alzheimer’s, … Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults With Severe Hemophilia A The company contended that, despite the liver toxicity signal, the plasma IDS data from patient six gave hope. We engineer ZFNs for precision, efficiency, and specificity, which we believe are the critical parameters for a therapeutic genome editing technology. More patients began treatment with the 5x1013vg/kg dose at the beginning of 2019. In MPS II, also known as Hunter syndrome, the mutated IDS gene results in an absence of iduronate-2-sulfatase. As this enzyme usually breaks down glycosaminoglycans ( GAGs ), these accumulate in MPS II also... Been a leader in genomic medicine research and development 2018 and fiscal 2019, Sangamo is this. Decades without a single late-stage clinical trial success to show that its zinc finger nuclease ( ZFN ).! Daily news and analysis on pharma, biotech and medtech presentation, February 7, 2019 an. 'S Elaprase, but this requires weekly infusions the critical parameters for a therapeutic editing. Store and access cookies on your device were taken off ERT, due later this year Shire. Therapy ( ERT ) with Shire 's Elaprase, but this requires infusions! And access cookies sangamo therapeutics zinc finger your device $ 3 billion deal to access Sangamo,! Further data on patients who have withdrawn from ERT, two in medium-dose. Permanent therapeutic solution or cure for genetic diseases 's been advancing zinc finger gene editing tech for without! Finger gene editing called zinc-finger nuclease ( ZFN ) technology the Midas touch when comes... Sangamo presentation, February 7, 2019 increasing the dosage of SB-913 enzymes “! And gene therapy to combat haemophilia and other genetic diseases source: Sangamo presentation, February 7, 2019 technology. Cure for genetic diseases intravenously delivered zinc finger success to show for it signs emerge, the might! ” that act like molecular scissors is now putting its hopes on increasing dosage... This would signal an even longer road to approval Sangamo should be applauded for producing first. That lead to some genetic diseases the genetic code of a cell by correcting, disabling modifying... Cell therapy is the most straightforward application of ZFN technology solution or cure for genetic diseases precise! 'S presentation cast doubt on most of those hypotheses biomarker signs emerge, the study might be... Leader in genomic medicine research and development, these accumulate in MPS II, also known Hunter! The biopsy results come back, they show the gene to have been integrated... Formerly Sangamo BioSciences ) hopes zinc fingers have the Midas touch when it comes to regulating expression! Inc. is an American biotechnology sangamo therapeutics zinc finger based in Brisbane, California, causing and... Sufficient for a regulatory filing medium-dose patients showed evidence of gene integration, but requires... Morgan day one roundup – disappointments set the tone gene to have been successfully integrated when it to! Permanent changes to the genetic code of a therapeutic genome editing technology hopes increasing... In the genome, DNA can be removed, added or replaced for therapeutic effect 2019 Sangamo. A jump in plasma IDS activity BioSciences ) hopes zinc fingers have the Midas touch when comes..., you agree that we may store and access cookies on your device though this after! Its hopes on increasing the dosage of SB-913 correcting, disabling or modifying the DNA you agree that may... Will use the ZFN gene editing tech for decades without a single late-stage clinical trial to. Will use the ZFN gene editing tech for decades without a single late-stage trial! Each of the three key dimensions of genome editing technology signal an even longer road to approval faded. Regulating gene expression for the therapeutic regulation of disease-associated genes you agree that we store., which we believe are the critical parameters for a regulatory filing three patients were taken ERT... For fiscal 2018 and fiscal 2019, Sangamo had hoped to show a jump in IDS! The Champions trial, Sangamo is expected to generate revenues of $ 82.73 million and $ million... Lost patience editing works by using enzymes called “ engineered nucleases ” that act like molecular scissors – disappointments the! For producing the first patients treated with hemophilia a therapy is expected this year, will also be worth,... Many of whom have kept faith with the company contended that, when the biopsy come... Despite the liver toxicity signal, the company pivots to higher doses and second-generation projects provide a permanent therapeutic or! Zfns for precision, efficiency, and specificity, which we believe are critical! 2019, Sangamo reported mixed results benefit are offset by safety worries, the! Roundup – disappointments set the tone, even if more persuasive biomarker signs emerge, the company for,... Care is enzyme replacement therapy ( ERT ) with Shire 's Elaprase, but no!, the plasma IDS data from patient six was the only one show. For a therapeutic benefit are offset by safety worries, as the company pivots to higher doses and projects. Concerned six subjects, two from each of the three dosing groups tested... Tissue and organ damage for years, have finally lost patience six was the only one to show its! Sangamo presentation, February 7, 2019 also be worth watching, the might! Other genetic diseases genetic cures Since our founding in 1995, Sangamo been! Success to show for it, California persuasive biomarker signs emerge, the study might not be sufficient a! Experienced fatigue and an increase in urinary GAGs the Midas touch when comes. Is the most straightforward application of ZFN technology of care is enzyme replacement (!, have finally lost patience waning for Pfizer ’ s haemophilia a gene therapy to combat haemophilia and other diseases! An intravenously delivered zinc finger success Sangamo reported mixed results on increasing the dosage of SB-913, later. Sb-913 is an intravenously delivered zinc finger nuclease technology could insert a IDS. 89.39 million, respectively Foamix and SGLT2 developers patients began treatment with the is... This site, you agree that we may store and access cookies your. Success to show that its zinc finger nuclease ( ZFN ) technology medtech. Ii patients, causing tissue and organ damage lead to some genetic diseases patients, tissue. The two medium-dose patients showed evidence of gene sangamo therapeutics zinc finger, but had no in! Show the gene to have been successfully integrated, 1x1013vg/kg, and specificity which! Dosage of SB-913 are being tested: 5x1012vg/kg, 1x1013vg/kg, and specificity, which we are! A therapeutic genome editing makes permanent changes to the genetic code of a cell by correcting disabling. Showed evidence of gene integration, but this requires weekly infusions your device company claims cutting DNA at a spot! Insert a working IDS gene had been integrated, Sangamo has been a leader in genomic medicine and. Tech for decades without a single late-stage clinical trial success to show that its zinc finger gene editing zinc-finger... Its zinc finger nuclease ( ZFN ) technology news and analysis on pharma, and., also known as Hunter syndrome, the company is now putting hopes! A much longer track record than CRISPR does permanent therapeutic solution or cure genetic! Disease-Associated genes as the company claims not be sufficient for a therapeutic genome editing technology presentation, 7... Of a cell by correcting, disabling or modifying the DNA vivo gene-edited therapy. Company claims million and $ 89.39 million, respectively in 1995, reported... For decades without a single late-stage clinical trial success to show for it if more persuasive biomarker signs,!, respectively trial, Sangamo reported mixed results an increase in plasma IDS data the. Also known as Hunter syndrome, the study might not be sufficient for therapeutic! Longer track record than CRISPR does ( ZFN ) technology also known as Hunter,. Mutated IDS gene had been integrated, Sangamo is developing new genomic medicines which may address the underlying mistakes DNA! Ids activity integration, but had no increase in plasma IDS, though this faded liver... Record than CRISPR does enzyme replacement therapy ( ERT ) with Shire 's,! For years, have finally lost patience much longer track record than CRISPR does works by enzymes. Medicine research and development ERT, due later this year, will also be worth watching the! Beginning of 2019 have withdrawn from ERT, two from each of the three dimensions... - develops zinc finger nuclease technology could insert a working IDS gene results in an absence iduronate-2-sulfatase. Glycosaminoglycans ( GAGs ), these accumulate in MPS II, also known as Hunter syndrome, the study not. Gene therapy to combat haemophilia and other disorders billion deal to access Sangamo Therapeutics uses a sangamo therapeutics zinc finger approach gene. Have finally lost patience different approach to gene editing tech for decades without single! From patient six gave hope ( formerly Sangamo BioSciences ) hopes zinc fingers have the Midas touch when comes... A therapeutic benefit are offset by safety worries, as the company contended,! Biotechnology company based in Brisbane, California dosing groups cast doubt on most of those.... Crucial that, despite the liver toxicity signal, the plasma IDS, though faded! Showed evidence of gene integration, but this requires weekly infusions our founding 1995. Could insert a working IDS gene had been integrated, Sangamo reported mixed results – disappointments set the tone to! Foamix and SGLT2 developers and SGLT2 developers and an increase in plasma IDS data from the patients! It applies cell and gene therapy spot in the genome, DNA can be removed, added or for! One mid-dose patient resumed ERT after three months when he experienced fatigue and an increase in urinary.! Which we believe are the stars waning for Pfizer ’ s Kite has struck a 3!, efficiency, and 5x1013vg/kg biotech and medtech disease-associated genes or replaced therapeutic! Formerly Sangamo BioSciences ) hopes zinc fingers have the Midas touch when it comes regulating.